- Home
- BNTC vs AVTX Comparison
BNTC vs AVTX Comparison
Compare BNTC & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTC | AVTX |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.7M | 328.4M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BNTC | AVTX |
|---|---|---|
| Price | $13.71 | $18.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $27.67 | ★ $40.57 |
| AVG Volume (30 Days) | 86.2K | ★ 1.5M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.94 | 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $9.85 | $4.55 |
| 52 Week High | $16.76 | $24.27 |
Technical Indicators
Market Signals| Indicator | BNTC | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.65 | 64.78 |
| Support Level | $12.79 | $13.13 |
| Resistance Level | $14.35 | $19.06 |
| Average True Range (ATR) | 0.74 | 1.09 |
| MACD | 0.32 | 0.52 |
| Stochastic Oscillator | 96.74 | 92.36 |
Price Performance
Historical ComparisonAbout BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.